Active Ingredient History

  • Now
Elagolix (ABT-620) is an oral gonadotropin-releasing hormone antagonist being studied for the treatment of endometriosis and uterine fibroids. The U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.   NCATS

  • SMILES: COc1cccc(C2=C(C)N(Cc3c(F)cccc3C(F)(F)F)C(=O)N(C[C@H](NCCCC(=O)O)c4ccccc4)C2=O)c1F
  • Mol. Mass: 631.6
  • ALogP: 5.54
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$16.7310 - $176.4525
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

elagolix | elagolix sodium | nbi-56418 | nbi-56418-na | obe2109 | r-(+)-4-(2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2h-pyrimidin-1-yl)-1-phenylethylamino)butyrate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue